HUT74982A - 2,5-diaryl-tetrahydrotiophene-, tetrahydrofurane-, and 1,3 diaryl-cyklopentane derivatives, and pharmaceutical preparations containing them - Google Patents

2,5-diaryl-tetrahydrotiophene-, tetrahydrofurane-, and 1,3 diaryl-cyklopentane derivatives, and pharmaceutical preparations containing them Download PDF

Info

Publication number
HUT74982A
HUT74982A HU9601854A HU9601854A HUT74982A HU T74982 A HUT74982 A HU T74982A HU 9601854 A HU9601854 A HU 9601854A HU 9601854 A HU9601854 A HU 9601854A HU T74982 A HUT74982 A HU T74982A
Authority
HU
Hungary
Prior art keywords
tetrahydrofuran
trans
propoxy
phenyl
hydroxy
Prior art date
Application number
HU9601854A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9601854D0 (en
Inventor
Tesfaye Biftu
Xiong Cai
Gurmit Grewal
Sajjat Hussoin
T Y Shen
Original Assignee
Cytomed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomed filed Critical Cytomed
Publication of HU9601854D0 publication Critical patent/HU9601854D0/hu
Publication of HUT74982A publication Critical patent/HUT74982A/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU9601854A 1994-01-06 1995-01-06 2,5-diaryl-tetrahydrotiophene-, tetrahydrofurane-, and 1,3 diaryl-cyklopentane derivatives, and pharmaceutical preparations containing them HUT74982A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/178,222 US5463083A (en) 1992-07-13 1994-01-06 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders

Publications (2)

Publication Number Publication Date
HU9601854D0 HU9601854D0 (en) 1996-09-30
HUT74982A true HUT74982A (en) 1997-03-28

Family

ID=22651708

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9601854A HUT74982A (en) 1994-01-06 1995-01-06 2,5-diaryl-tetrahydrotiophene-, tetrahydrofurane-, and 1,3 diaryl-cyklopentane derivatives, and pharmaceutical preparations containing them

Country Status (8)

Country Link
US (3) US5463083A (fr)
EP (1) EP0749306A4 (fr)
JP (1) JPH09509651A (fr)
CN (1) CN1143319A (fr)
AU (1) AU696227B2 (fr)
CA (1) CA2180123A1 (fr)
HU (1) HUT74982A (fr)
WO (1) WO1995018610A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463083A (en) * 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5434151A (en) * 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
CA2140034A1 (fr) 1992-07-13 1994-01-20 Xiong Cai 2,5-diaryltetrahydro-thiophenes, -furanes et analogues pour le traitement des troubles inflammatoires et immuns
US5792776A (en) * 1994-06-27 1998-08-11 Cytomed, Inc., Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
MX9606635A (es) * 1994-06-27 1997-12-31 Cytomed Inc Compuestos y metodos para el tratamiento de desordenes cardiovasculares, inflamatorios e inmunes.
US5750565A (en) * 1995-05-25 1998-05-12 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5703093A (en) * 1995-05-31 1997-12-30 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
CN1052481C (zh) * 1996-06-28 2000-05-17 中国人民解放军第二军医大学 一种新型血小板激活因子拮抗剂及其制备方法
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
CA2342156A1 (fr) 1998-07-03 2000-01-13 Andappan Murugaiah Subbaiah Murugaiah Procedes de synthese de compose de tetrahydrofuran substitue
EP1094805A4 (fr) 1998-07-03 2002-08-28 Millennium Pharm Inc Composes alicycliques d'oxygene substitues, procedes de synthese de ces composes
US6255498B1 (en) 1998-10-16 2001-07-03 Millennium Pharmaceuticals, Inc. Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans
AU1122300A (en) * 1998-10-16 2000-05-08 Leukosite Incorporated Pharmaceutical formulations useful to treat inflammatory and immune disorders
EP1311269B1 (fr) 2000-08-04 2012-02-29 DMI Biosciences, Inc. Methode d'utilisation de dicetopiperazines et composition contenant ces substances
DK1571970T3 (da) * 2002-10-02 2011-11-28 Dmi Biosciences Inc Diagnose og monitorering af sygdomme
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
ES2572975T3 (es) 2003-05-15 2016-06-03 Ampio Pharmaceuticals, Inc. Tratamiento de enfermedades mediadas por los linfocitos T
EP1670445A2 (fr) * 2003-09-17 2006-06-21 Decode Genetics EHF. Methodes de prevention ou de traitement de la recurrence de l'infarctus du myocarde
EP2300011A4 (fr) 2008-05-27 2012-06-20 Dmi Life Sciences Inc Procédés et composés thérapeutiques
EP2424521A4 (fr) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
EP3721884A1 (fr) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Traitement de maladies articulaires dégénératives avec da-dkp (= diketopiperazine aspartyl-alanyl)
US9925300B2 (en) 2011-10-10 2018-03-27 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
WO2013063413A1 (fr) 2011-10-28 2013-05-02 Ampio Pharmaceuticals, Inc. Traitement de la rhinite
CN102603707B (zh) * 2012-02-10 2013-06-19 中国科学院化学研究所 2,3,4,5-四(3’,4’-二羟基苯基)噻吩及其作为maldi基质分析小分子的应用
CA2906864A1 (fr) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions pour la mobilisation, l'ecotropisme, l'expansion et la differenciation de cellules souches et leurs methodes d'utilisation
JP6723222B2 (ja) 2014-08-18 2020-07-15 アンピオ ファーマシューティカルズ，インコーポレイテッド 関節病態の治療
WO2016209969A1 (fr) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Utilisation de fractions d'albumine de sérum humain de bas poids moléculaire pour traiter les maladies

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2690988A (en) 1952-12-24 1954-10-05 Stauffer Chemical Co Insecticidal substituted 1, 3-dithiolanes and method of application
US2913494A (en) 1957-10-02 1959-11-17 American Cyanamid Co Process for the quaternization of 3-diethylamino-1-cyclohexyl-1-phenyl-propanol-1 with ethyl iodide
US3038004A (en) 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
AT290523B (de) 1962-01-05 1971-06-11 Merck & Co Inc Verfahren zur Herstellung neuer α-(3-Indolyl)-carbonsäuren
US3647858A (en) 1970-05-01 1972-03-07 Merck & Co Inc Process for preparing 1-benzylidene-3-indenyl acetic acids
US3654349A (en) 1970-05-01 1972-04-04 Merck & Co Inc Substituted indenyl acetic acids
US3714226A (en) 1970-06-09 1973-01-30 Merck & Co Inc Phenyl benzoic acid compounds
US3852601A (en) * 1971-07-15 1974-12-03 Ital Elettionica Spa Scanning device for scintigraphy according to three orthogonal planes
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4656190A (en) 1983-11-14 1987-04-07 Merck & Co., Inc. Indene derivatives and their use as PAF-antagonists
US4539332A (en) 1983-11-14 1985-09-03 Merck & Co., Inc. 2,5-Diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
US4757084A (en) * 1984-02-29 1988-07-12 Merck & Co., Inc. 2,5-diaryl tetrahydrothiophenes and analogs thereof as PAF-antagonists
US4595693A (en) 1984-06-04 1986-06-17 Merck & Co., Inc. Method of use of 2,5-diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
US4871756A (en) 1985-03-20 1989-10-03 Merck Frosst Canada, Inc. Leukotriene antagonists
US4604407A (en) 1985-04-04 1986-08-05 E. R. Squibb & Sons, Inc. Hydroxamates
NZ215866A (en) * 1985-04-22 1989-11-28 Merck & Co Inc 2,5-di(aryl/heterocyclyl) tetrahydro-furans and pharmaceutical compositions
US4876346A (en) 1985-05-02 1989-10-24 American Home Products Corporation Quinoline compounds
US4891363A (en) 1985-07-26 1990-01-02 Sankyo Company Limited Cyclic ether derivatives and their use
DE3701344A1 (de) 1986-01-21 1987-07-23 Boehringer Ingelheim Kg Neue thieno-1,4-diazepine
FR2601016B1 (fr) * 1986-07-04 1988-10-07 Rhone Poulenc Sante Nouveaux derives du 1h,3h-pyrrolo (1,2-c) thiazole, leur preparation et les compositions pharmaceutiques qui les contiennent
US4910206A (en) * 1986-07-14 1990-03-20 Sandoz Pharmaceuticals Corp. 5-hetero-or aryl-substituted-imidazo(2,1-a)isoquinolines and their use as PAF receptor antagonists
DE3724031A1 (de) 1986-07-22 1988-01-28 Boehringer Ingelheim Kg Neue hetrazepine und verfahren zu ihrer herstellung
DE3724164A1 (de) 1986-07-25 1988-01-28 Boehringer Ingelheim Kg Neue 1,4-benzodiazepine, ihre herstellung und verwendung
DE3778248D1 (de) 1986-08-21 1992-05-21 Merck & Co Inc 1,3-diarylcyclopentane und deren abkoemmlinge als paf-antagonisten.
US4841968A (en) 1986-09-26 1989-06-27 Southern Research Institute Antithrombotic/thrombolytic suture and methods of making and using the same
GB2197650A (en) 1986-11-21 1988-05-25 Merck & Co Inc Process for preparing 2,5-diphenyl tetrahydrofurans and analogs thereof
US4873259A (en) 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
CN1030415A (zh) * 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
US4916145A (en) * 1987-07-10 1990-04-10 Hoffmann-La Roche Inc. Substituted n-[(pyridyl)alkyl]aryl-carboxamide
GB2209031A (en) 1987-08-24 1989-04-26 Merck & Co Inc Processes for preparing 1,3-diaryl cyclopentanes and derivatives thereof as PAF antagonists
CA1334975C (fr) 1987-11-13 1995-03-28 James H. Holms Composes inhibiteurs de type lipoxygenase contenant des groupes furane et pyrrole
JPH01149764A (ja) * 1987-12-07 1989-06-12 Green Cross Corp:The ビス−ｓ−アルキルベンゼン誘導体
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
NZ227287A (en) 1987-12-21 1992-01-29 Merck & Co Inc 2,5-diaryl tetrahydrofurans and medicaments
US4996203A (en) * 1987-12-21 1991-02-26 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
US4845129A (en) 1988-03-14 1989-07-04 Sandoz Pharm. Corp. Diaryl substituted cyclopentane and cyclopentene derivatives
EP0338993A1 (fr) * 1988-04-21 1989-10-25 Sandoz Ag 4H-thiéno[2,3-e][1,2,4]triazolo[3,4-c][1,4]diazépines substituées par aryle sur la position 6
US4992428A (en) * 1988-05-05 1991-02-12 Sandoz Pharm. Corp. 5-aryl-substituted-2,3-dihydro-imidazo[1,2-a]furo- and thieno pyridines
EP0365089A3 (fr) * 1988-10-18 1991-06-05 Merck & Co. Inc. 2-Aryl-5(3-méthoxy-5-(hydroxypropylsulphonyl)-4-propoxyphényl) tétrahydrothiophène et analogues
FI95708C (fi) * 1988-10-31 1996-03-11 Eisai Co Ltd Analogiamenetelmä 1,4-diatsepiinijohdannaisen ja sen farmaseuttisesti sopivan suolan valmistamiseksi
DE3936828A1 (de) 1988-11-06 1990-05-10 Boehringer Ingelheim Kg Neue hetrazepine
US5234950A (en) 1988-12-23 1993-08-10 Imperial Chemical Industries Plc Tetrahydrofuran derivatives
US5175183A (en) 1989-02-01 1992-12-29 Abbott Laboratories Lipoxygenase inhibiting compounds
DE4006471A1 (de) 1989-03-03 1990-09-06 Boehringer Ingelheim Kg Neue thienodiazepine
FR2644456B1 (fr) * 1989-03-17 1991-07-05 Rhone Poulenc Sante Nouveaux derives du 1h, 3h-pyrrolo(1,2-c)thiazolecarboxamide-7, leur preparation et les compositions pharmaceutiques qui les contiennent
GB8907401D0 (en) * 1989-04-01 1989-05-17 Pfizer Ltd Therapeutic agents
US5011847A (en) 1989-06-08 1991-04-30 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
US4977146A (en) * 1989-06-08 1990-12-11 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
US5001123A (en) 1989-06-08 1991-03-19 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
GB2233974A (en) * 1989-07-22 1991-01-23 Pfizer Ltd Dihydropyridine antiinflammatory agent
PH30133A (en) * 1989-09-07 1997-01-21 Abbott Lab Indole-, benzofuran-, and benzothiophene-containing lipoxygenase inhibiting compounds
US5037853A (en) 1989-12-28 1991-08-06 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
GB9009469D0 (en) 1990-04-27 1990-06-20 British Bio Technology Compounds
US5244896A (en) 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
JP3007138B2 (ja) 1990-11-27 2000-02-07 ファイザー製薬株式会社 新規なヒドロキサム酸とｎ―ヒドロキシ尿素誘導体およびそれらの組成物
US5110831A (en) 1990-11-30 1992-05-05 Du Pont Merck Pharmaceutical Company Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
JPH0730061B2 (ja) 1991-02-07 1995-04-05 ファイザー製薬株式会社 ヒドロキサム酸誘導体および組成物
EP0574510B1 (fr) * 1991-03-04 2001-09-05 Center For Innovative Technology 2,4-diaryl-1,3-dithiolanes utilises comme antagonistes de recepteurs de facteurs d'activation des plaquettes et inhibiteurs de 5-lipoxygenase
US5420164A (en) 1991-04-04 1995-05-30 Yoshitomi Pharmaceutical Industries, Ltd. Cycloalkylurea compounds
RU2059603C1 (ru) * 1991-05-09 1996-05-10 Хоффманн-Ля Рош АГ ПРОИЗВОДНЫЕ α -ЗАМЕЩЕННЫХ АРИЛУКСУСНЫХ КИСЛОТ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
US5147893A (en) 1991-05-09 1992-09-15 G. D. Searle & Co. Cyclic phenolic thioethers
GB9114337D0 (en) 1991-07-03 1991-08-21 British Bio Technology Compounds
US5183818A (en) 1991-08-27 1993-02-02 Abbott Laboratories Arylalkylether and arylalkylthioether inhibitors of lipoxygenase enzyme activity
GB9200210D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
US5169854A (en) 1992-02-26 1992-12-08 Abbott Laboratories N-substituted-furylalkenyl hydroxamic acid and N-hydroxyurea compounds having lipoxygenase inhibitory activity
US5530141A (en) 1992-03-04 1996-06-25 Center For Innovative Technology 2,4-diaryl-1,3-dithiolanes; 2,4-diaryl-1,3-dioxolanes; 2,4-diaryl-1,3-oxathiolanes; and 2,5-diaryl-1,3-oxathiolanes for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5639782A (en) 1992-03-04 1997-06-17 Center For Innovative Technology Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors
US5187192A (en) 1992-03-13 1993-02-16 Abbott Laboratories Cyclobutyl derivatives having lipoxygenase inhibitory activity
US5326787A (en) 1992-05-12 1994-07-05 Abbott Laboratories Cycloalkyl N-hydroxy derivatives having lipoxygenase inhibitory activity
CA2140034A1 (fr) * 1992-07-13 1994-01-20 Xiong Cai 2,5-diaryltetrahydro-thiophenes, -furanes et analogues pour le traitement des troubles inflammatoires et immuns
US5358938A (en) 1992-07-13 1994-10-25 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5434151A (en) 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5463083A (en) 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5334843A (en) 1992-08-17 1994-08-02 Zeman Herbert D Composite scintillator screen
WO1994004537A2 (fr) * 1992-08-20 1994-03-03 Cytomed, Inc. Agents a double fonctionnalite anti-inflammatoire et d'immunosuppression
US5288751A (en) 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
ES2062943B1 (es) 1993-03-23 1995-11-16 Uriach & Cia Sa J Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
MX9606635A (es) 1994-06-27 1997-12-31 Cytomed Inc Compuestos y metodos para el tratamiento de desordenes cardiovasculares, inflamatorios e inmunes.

Also Published As

Publication number Publication date
EP0749306A4 (fr) 1997-04-16
US5463083A (en) 1995-10-31
HU9601854D0 (en) 1996-09-30
US6420392B1 (en) 2002-07-16
CA2180123A1 (fr) 1995-07-13
AU696227B2 (en) 1998-09-03
CN1143319A (zh) 1997-02-19
EP0749306A1 (fr) 1996-12-27
US5741809A (en) 1998-04-21
WO1995018610A1 (fr) 1995-07-13
JPH09509651A (ja) 1997-09-30
AU1597495A (en) 1995-08-01

Similar Documents

Publication Publication Date Title
HUT74982A (en) 2,5-diaryl-tetrahydrotiophene-, tetrahydrofurane-, and 1,3 diaryl-cyklopentane derivatives, and pharmaceutical preparations containing them
US5856323A (en) Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US4757084A (en) 2,5-diaryl tetrahydrothiophenes and analogs thereof as PAF-antagonists
KR100276570B1 (ko) 심혈관질환염증성질환및면역성질환치료용화합물
US5358938A (en) Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US4595693A (en) Method of use of 2,5-diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
US5792776A (en) Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
EP0273647A1 (fr) Dérivés de coumaranne, leur préparation et leur utilisation
KR102536408B1 (ko) Hsp90 저해제 및 hsp70 유도제로서의 개질된 에터기를 가진 바이페닐 아마이드
MX2014003958A (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
US5648486A (en) Compounds and methods for the treatment of inflammatory and immune disorders
EP2771336B1 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
EP0650485B1 (fr) 2,5-diaryle tetrahydro-thiophenes, -furanes et analogues utilises dans le traitement de troubles inflammatoires et immuns
EP0154887B1 (fr) 2,5-Diaryl tétrahydrothiophénes et analogues, en tant qu'antagonistes de PAF
US5011847A (en) 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
JPH08505362A (ja) Ｐａｆレセプター拮抗剤及び５−リポキシゲナーゼ阻害剤としての、２，４−ジアリール−１，３−ジチオラン、２，４−ジアリール−１，３−ジオキソラン、２，４−ジアリール−１，３−オキサチオラン、及び２，５−ジアリール−１，３−オキサチオラン
JPH0374383A (ja) Ｐａｆ拮抗体としての新規な２，５‐ジアリールテトラヒドロフラン及びその類似体
US5530141A (en) 2,4-diaryl-1,3-dithiolanes; 2,4-diaryl-1,3-dioxolanes; 2,4-diaryl-1,3-oxathiolanes; and 2,5-diaryl-1,3-oxathiolanes for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
EP0008073A1 (fr) Diazacycloalcènes thio-substitués, procédé pour leur préparation et leurs compositions pharmaceutiques
DE60300307T2 (de) Imidazolinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
JPH085871B2 (ja) クマラン誘導体およびその製造法
JP2000501741A (ja) Ｐｄｅ▲ｉｖ▼阻害剤としてのジフェニルピリジルエタン誘導体
CH649544A5 (de) Thienyl- und benzothienyl-tertiaere butylaminophenoxypropanole.